Covid Vaccine Race

Facilities in Connecticut had an outbreak prior to vaccinating their residents, which in turn controlled the spread effectively.

Reproduction number should govern allocation of the shot, researchers say.

New polls shows confidence in AstraZeneca vaccine plummets in Europe.

After a year of setbacks, AZD1222 has been associated with 100% prevention of severe COVID-19 in US trial participants. Could emergency authorization come soon?

COVID-19 vaccine development demanded an adults-first approach. A year in, children are being invited to participate in trials in hopes of getting the pediatric population vaccinated later this year.

Regardless of symptom status, the rate of participants positive for pan-immunoglobulins with neutralizing antibodies at baseline remained stable throughout 2020.

The new findings support increased protection from reinfection up to 6 months after first testing positive, though older patients are at greater risk of reinfection.

Researchers and clinicians continually failed to connect with the greater public on matters of the pandemic. What drove the divide between the already distanced groups?

A 2-dose vaccination regimen did not show protection against mild-to-moderate disease due to the B.1.351 variant.

The vaccine is currently authorized for use under an EUA in individuals 18 years of age and older.

There are many reasons for COVID-19 vaccine hesitancy, including its side effects. Here is an examination of side effects in those who have been vaccinated.

Number of cases surge in the pacific island nation of Papua New Guinea.

The data additionally show a 94% prevention against asymptomatic SARS-CoV-2 infection, at a time when the country's dominant strain was the B.1.1.7 variant.

France announces a relaxation on restrictions involving international travel outside the EU.

This Emergency Use Listing (EUL) of this single-shot vaccine opens up the door to much of the developing world to gain access to it.

Though the product is authorized more than 70 countries, there is currently no reported US trial data, nor application for authorization to the FDA.

Strong immunologic responses to vaccination for SARS-CoV-2 in COVID-19 survivors suggest that first of 2-dose vaccination could suffice.

The investigational candidate has shown to be 55% and 86.3% effective respectively.

The acquisition of the Johnson & Johnson pharmaceutical company's vaccine would likely be completed in the latter half of this year.

A UK health authority representative discussed the possibility of a fall season booster to prevent another winter surge of cases.

Though small in scale and still cautious, the new advisory reflects confidence in SARS-CoV-2 mitigation among a more vaccinated population.

The statement comes on the same day as a rare production agreement between pharmaceutical rivals, and Texas' announced lift of spread mitigation measures.

The Biden Administration is set to announce the deal officially about a partnership for the biopharmaceutical companies today.

Prime Minister Narendra Modi of India receives vaccine as country begins next phase of program.

Courtesy of HCPLive, here's a look at 3 new pandemic talking points covered at the annual allergy and asthma meeting.

The VRBPAC voted 22-0 with no abstentions to support the benefit-risk profile associated with Ad26.COV2.S on Friday night.

The US Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) recommendation paves the way for the authorization.

The country has no domestic production, and the government has been accused of not acquiring doses quickly enough.

If approved, the decision could have a significant impact on the mass vaccination programs.

Vaccine clinical trials have fallen short of diversity guidelines during the past decade, with minority groups underrepresented and key data missing in many trials, a new study found.